Metraipolis › archive › dc_04231a458a2b
Pathological response to pembrolizumab-based neoadjuvant therapy in ER-low vs. ER-zero breast cancer: a Swedish population-based cohort study — Europe PMC PMID:41316480
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41316480
- DOI
- 10.1186/s13058-[numero omesso]-3
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T04:00:35.746Z
- SHA-256 of the archived text
c806e1e0b833b49ee2e5400880b955e3372af0ab1c90e96dd0baff8f881defa3- Stable URL of this page
https://metraipolis.com/documento/dc_04231a458a2b
How to cite
Pathological response to pembrolizumab-based neoadjuvant therapy in ER-low vs. ER-zero breast cancer: a Swedish population-based cohort study — Europe PMC PMID:41316480 — Europe PMC (en), https://europepmc.org/article/MED/41316480 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_04231a458a2b (Metraipolis archive dc_04231a458a2b, sha256 c806e1e0b833b49ee2e5400880b955e3372af0ab1c90e96dd0baff8f881defa3)
BibTeX
@misc{dc04231a458a2b,
title = {Pathological response to pembrolizumab-based neoadjuvant therapy in ER-low vs. ER-zero breast cancer: a Swedish population-based cohort study — Europe PMC PMID:41316480},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41316480},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_04231a458a2b; sha256 c806e1e0b833b49ee2e5400880b955e3372af0ab1c90e96dd0baff8f881defa3},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41316480. Agents can read the archived copy with the MCP tool read_document.